Eisai US
4523
Performance
About Eisai US
Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., dedicated to human health care (hhc) by prioritizing the needs of patients and their families. Based in New Jersey, Eisai focuses on developing innovative therapies primarily in the fields of oncology and neurology, particularly addressing dementia-related and neurodegenerative diseases. The company integrates discovery, development, and marketing efforts across various locations, including Massachusetts and Pennsylvania for research and Maryland and North Carolina for global demand chain operations.
Recent News
Eisai, Biogen Receive Extended FDA Review for Lecanemab Subcutaneous Starting Dose
Clinical Trial Failures of 2026
Eisai Sets FY2028 Revenue Goal of ¥1 Trillion ($6.7B) on Oncology, Dementia Growth
FDA Pushes Leqembi Subcutaneous Start‑Dose Review to Aug. 24, 2026
Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review
Sutro Biopharma Inc (STRO) Q1 2026 Earnings Call Transcript
FDA Delays Leqembi Decision; Artiva Raises $300M; Pharvaris Prices Offering
Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.
What’s the Deal with Alzheimer’s Disease and Amyloid?
In the Clinic for April 22, 2026
Biogen Ready to Catch Alzheimer’s Patients Transitioning Off Lilly’s Kisunla
Goldman Sachs Sets New Biogen Stock Price Target on Bold Alzheimer's Bet
Eli Lilly Shares Surge on a Beat-and-Raise, Proving the Stock's Swoon Was a Mistake
Effect of ‘Gamechanger’ Alzheimer’s Drugs ‘Trivial’, Review Concludes
Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain
Shanghai Start-Up Launches to Develop Trispecific Antibodies
CMS's Medicare Price Negotiations Start Round Three
Diagnostics Lag Is Holding Back New Therapies, Says Study
Leqembi Starts to Deliver for Eisai and Biogen
What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days
Medicare Spending on New Alzheimer’s Drugs Falls Short of Billion‑Dollar Forecasts
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
Could Alzheimer's Be Predicted with a Finger-Prick Test?
Angelini Inks $4.1B Catalyst Buy to Enter US Rare Disease Market
Biogen’s Alzheimer’s Results Bolster Tau Theory—And Denali’s Next Gen Candidate
The New Gold Rush in Brain Science
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
Roche Gets Second European Approval for Alzheimer’s Test
Biogen, Eisai Hit with 3-Month Delay for Starting SubQ Alzheimer’s Therapy
Eisai, Biogen Face Delay to Subcutaneous Leqembi
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Eight Swedish Companies Spearheading the Country’s Biotech Scene in 2026
Developers Back Alzheimer’s Drugs Despite Report Suggesting Lack of Efficacy
FDA Kicks Off Review of Takeda's Narcolepsy Hopeful
Eisai Gains Henlius Therapy; LB Pharma Snags $100M in Funding
Ray's Upscaled Series B, and Other Biofinancings
Biogen's Stock Slumps as Biosimilars Hit MS Sales and Alzheimer Setbacks Loom
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
Most Sustainable Pharma and Biotech Companies in 2026, According to Corporate Knights
FDA Extends Review of Eisai/Biogen Subcutaneous Leqembi to Aug 2026
Biogen Inc (BIIB) Q1 2026 Earnings Call Transcript
Harmeier Returns to Lead Roche Venture Fund
Recent Deals
No recent deals for this company.